TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
|
|
- Maud Pope
- 5 years ago
- Views:
Transcription
1 TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital
2 Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer J. Segelman1,*, F. Granath2, T. Holm1, M. Machado3, H. Mahteme4, A. Martling1 British Journal of Surgery 2012; 99: patients 8.3 % had synchronous or metachronous peritoneal carcinomatosis 4.3 % had synchronous PC 4.8 % cumulative incidence of metachronous PC in 4.8 % PC was the first and only localization of metastases
3 Effect of systemic chemotherapy on colorectal peritoneal carcinomatosis lack of data especially concerning PC as the only localization of metastases median survival of 6 months in unselected patients with older chemotherapies -> 5-year OS 5 % median survival less than 24 months in highly selected patients with modern chemotherapies -> 5-year OS 13 %
4 Franko J, Shi Q, Goldman CD et al. 20;30(3):263-67, OVERALL SURVIVAL OF PATIENTS WITH PC OF CRC ORIGIN pccrc median OS 14 months 5-year survival 4.1 % (A) leucovorin, fluorouracil, oxaliplatin (B) irinotecan, leucovorin, fluorouracil (C) irinotecan and oxaliplatin
5 Philosophy of CytoReductive Surgery (CRS) and Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) Peritoneum can be considered as an organ itself and as the third route of spreading of metastases in addition to hematogenous and lymphatic metastases. Thus, in selected patients, when peritoneal afficions can be technically removed, total cure is possible to achieve.
6 Cytoreduction and HIPEC in the Netherlands: NationwideLong-term Outcome Following the Dutch Protocol A. M. J. Kuijpers et al. Ann Surg Oncol 2013 OS overall survival PFS progression-free survival CRC median PFS 15 months median OS 33 months 3-y survival 46 % 5-y survival 31 % PMP median PFS 53 months median OS 130 months 3-y survival 77 % 5-y survival 65 %
7 Jan Franko MD, PhD, Zuhaib Ibrahim MD, Niraj J. Gusani MD, et. al,cancer 2010; 116: median survival 34.7 months vs months presence of liver metastases was negative predictor of survival (HR 2.13) Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis control group inclusion criteria: 1) asymptomatic PC 2) aggressive chemotherapy 3) primary tumor removed
8 Goere D, Malka D, Tzanis D et al. 2013, 257(6): CURATION RATE AFTER CRS AND HIPEC FOR PC OF COLORECTAL ORIGIN 107 patients years year survival 35 % 10-year survival 15% 16 % disease-free after 5 years
9 ... Selected patients with colorectal carcinomatosis have 5- year survival of 25 to 30 %. Compare to 30-40% 5-year survival and 17% cure after resection of colorectal cancer liver metastases or 18 % 5-year survival after radical surgery for pancreatic cancer
10 Carefully selected patients with peritoneal carcinomatosis from colorectal origin benefit from cytoreductive surgery combined with intraperitoneal chemotherapy. Questions: How do we select the right patients considering 0-18 % mortality and % morbidity rate associated with CRS and HIPEC? How do we find the right patients?
11 Prognostic factors affecting survival after CRS and HIPEC in patients with colorectal PC PCI CC-rate number of involved areas small bowel involvement liver metastases (number of?) progression during neoadjuvant chemotherapy adjuvant chemotherapy tumor differentiation, tumor histology serum tumor markers
12 Impact of tumor mass on survival after radical surgery Limited peritoneal cancer index ( <9, <10, <12?) or limited peritoneal cancer score are positive predictors of survival. Benizri E et al. World J Surg Oncol 2012: 10: 56-. Yonemura Y et al. ScientificWorldJournal 2013 Maggiori L et al. Ann Surg 2013; 258: Verwaal VJ et al. Br J Surg 2004; 91: PCI is reliable tool of measuring the extent of PC, because inter-surgeon concordance (> 90 %) before and after surgery is high. Elias D et al. EJSO ;
13 adopted by Paul Sugarbaker
14 Goere D, Malka D, Tzanis D et al. 2013, 257(6): Overall survival in 107 patients after CRS and IPC according to peritoneal cancer index. median PCI: 4 (3-16) in cured 12 (2-36) in noncured
15 Number of affected regions Age Sex Verwaal VJ et al. 2004; 91: Location (app / colon) Location (rectum / colon) Recurrence or primary Differentiation Signet cell or non-signet cell No of affected regions
16 Small bowel involvement Yonemura Y et al. ScientificWorldJournal 2013
17 Surgical radicality: CC-0 vs. CC-1 CCR-O: 5-y survival 20% CCR-1: 5-year survival 9.9% Yonemura Y et al. ScientificWorldJournal 2013 Benizri E et al. World J Surg Oncol 2012; 10:56
18 Surgical radicality: CC-0 vs. CC-1 Passot G et al. Ann Surg 2012; 256:
19 Synchronous liver metastases and PC Maggiori L et. al. 2013;258: patients with PC + LM, 61 patients with PC 3-year overall and disease-free survival: 40 % and 6 % in PC + LM group 60% and 27 % in PC only group
20 Synchronous liver metastases and PC Maggiori L et. al. 2013;258: Median survival: PCI < 12 and no LM 76 months PCI < 12 and 1-2 LMs 40 months PCI >= 12 and > 2 LMs 27 months
21 Progression of PC during neoadjuvant chemotherapy Passot G et al. Ann Surg 2012; 256(1): Progression during neoadjuvant chemotherapy was not a negative predictor of survival after CRS and HIPEC. p = 0.475
22 Effect of adjuvant chemotherapy Passot G et al. Ann Surg 2012; 256(1): p = 0.049
23 Tumor differentiation Age Sex Verwaal VJ et al. 2004; 91: Location (app / colon) Location (rectum / colon) Recurrence or primary Differentiation Signet cell or non-signet cell No of affected regions
24 Effect of tumor differentiation and histology Median and 5-year survival after CRS and HIPEC: 25.9 months and 24.6 % in differentiated 10.7 months and 0 % in poorly differentiated Yonemura Y et al. The Scientific World Journal Volume 2013 (2013), Article ID , 7 pages
25 Patients at risk for colorectal PC previous synchronous PC ovarian metastases tumor perforation liver metastases venous and perineural invasion right-sided colonic cancer T3-T4 N1-N2 fewer than 12 LNs examined emergency procedures non-radical resection
26 Synchronous ovarian metastases with primary tumor without synchronous PC do occur in % of all colorectal cancers -> PC in 62 % of patients at second-look after 12 months -> PC in 56 % of patients in imaging studies after surgery level of evidence 3b to 4 (case-control study,case series) Honore C et al.2013; 20:
27 Synchronous PC with the primary tumor in about 4.8 % of patients scheduled for curative surgery -> PC in second-look after 12 months in 54% of patients with completely resected synchronous PC level of evidence 3b to 4 (case-control study,case series) Honore C et al. 2013; 20:
28 Perforated primary tumor Overall tumor perforation rate is about 1 to 8 %. -> PC in 27 % of patients having second-look after 12 months of primary operation with tumor perforation. Honore C et al.2013; 20:
29 Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer J. Segelman1,*, F. Granath2, T. Holm1, M. Machado3, H. Mahteme4, A. Martling1 British Journal of Surgery 2012; 99: patients operated in Stockholm County followed until 2010 metachronous PC in 447 (4.2 %) diagnosis of metacronous PC after median of 16 ( ) months
30 Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer J. Segelman1 et al. British Journal of Surgery 2012; 99: Statistically significant risk factors for metachronous PC: colon cancer (especially right-sided) advaced tumor, T3-4 advanced node status (N 1-2) less than 12 investigated nodes emergency surgery non-radical resection
31 Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer J. Segelman et al. British Journal of Surgery 2012; 99: patients had PC as the sole site of metastases after resection of Stage I-III primary tumor. -> about half of these could be candidates for radical surgery only 1 % of Stage I-III patients would benefit from second-look
32 Laparoscopy in evaluating PC of colorectal origin Iversen LH et al. BJS 2013;100: Laparoscopy succeeded technically in all 26 patients with CRC originated PC. 45 patients 14 synchronous PC with CRC 12 metachronous PC after CRC 19 other than CRC originated CRC patients selected for CRS and HIPEC on the basis of laparoscopy: 7 patients with metachronous PC and 8 patients with synchronous PC
33 Laparoscopy in evaluating PC of colorectal origin CRS and HIPEC was not possible Iversen LH et al. BJS 2013;100: in 1 of 8 synchronous PCs in 5 of 7 metachronous PCs Laparoscopy most often failed to recognize retroperitoneal and hepatic pedicle carcinomatosis.
34 Conclusions Carefully selected patients with colorectal carcinomatosis benefit from CRS and HIPEC and can achieve about 30 % 5-year survival and 16 % 5-year disease-free survival. In order to prevent unnecessary suffering of patients and use of limited health care resources, we should limit CRS and HIPEC to patients with good prognostic factors and true possibility of CC-0 surgery.
35 Conclusions A second look (within 6 to 12 months?) laparotomy/scopy should be considered in patients with synchronous ovarian metastases, synchronous peritoneal carcinomatosis or tumor perforation. Patients with peritoneal progression during neoadjuvant treatment or with 1 to 2 liver metastases should not be automatically excluded from CRS and HIPEC. Patients possibly benefit from adjuvant chemotherapy after CRS and HIPEC.
COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini
UNIVERSITY OF PERUGIA Department of General and Emergency Surgery Chief: Prof. Annibale Donini COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini COLON CANCER IS A HIGHLY FREQUENT NEOPLASIA
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationPlanned relaparotomy following curative resection of a locally advanced gastrointestinal cancer
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned
More informationHow to deal with patients with isolated peritoneal metastases
ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE
More informationCurrent standard in treatment of peritoneal carcinomotisis. Data behind the HIPEC trials
Current standard in treatment of peritoneal carcinomotisis Data behind the HIPEC trials Overview Peritoneal carcinomatosis STANDARD treatment HIPEC Results of treatment Counter side of treatment Peritoneal
More informationCRS e HIPEC: Efficacia e Limiti
CRS e HIPEC: Efficacia e Limiti Marcello Deraco M.D. Responsabile Tumori Peritoneali The Concept of Cytoreductive Surgery Means a complete removal of all macroscopic tumor in the peritoneal cavity; It
More informationThis is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.
Uppsala University This is a submitted version of a paper published in European Journal of Surgical Oncology. Citation for the published paper: Cashin, P., Graf, W., Nygren, P., Mahteme, H. (2012) "Cytoreductive
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationCytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
Ann Surg Oncol (2013) 20:4224 4230 DOI 10.1245/s10434-013-3145-9 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
More informationHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0396 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Related Coverage Resources
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationPseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Case Presentation 72M 3 weeks abdominal distension and lower abdominal pain. 3 weeks constipation w/ 2-3 BM per week. Post-prandial epigastric/substernal
More informationManagement of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500
More informationHIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde
UvA-DARE (Digital Academic Repository) HIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde Link to publication Citation for published version (APA): Braam, H. J.
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationResults of a French Multicentric Analysis
Peritonectomy, Perioperative and Intraoperative Intraperitoneal Chemotherapy for Carcinosis Arising from Gastric Cancer Results of a French Multicentric Analysis 17 th -19 th 2008 Report Digestive and
More informationResults of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
More informationHIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde
UvA-DARE (Digital Academic Repository) HIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde Link to publication Citation for published version (APA): Braam, H. J.
More informationCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis
JBUON 2017; 22(6): 1547-1553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective
More informationLocally Advanced Colon Cancer. Feiran Lou MD. MS. Richmond University Medical Center Department of Surgery
Locally Advanced Colon Cancer Feiran Lou MD. MS. Richmond University Medical Center Department of Surgery Case 34 yo man presented with severe RLQ abdominal pain X 24 hrs. No nausea/vomiting/fever. + flatus.
More informationColorectal peritoneal metastases and IMPACT
Colorectal peritoneal metastases and IMPACT Vicki Pleavin-Evans Peritoneal Malignancy Clinical Nurse Specialist PMI Basingstoke Basingstoke and North Hampshire Hospital Aldermaston Road, Basingstoke, Hampshire
More informationCRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017
CRS and HIPEC for Colorectal Cancer Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 Peritoneal Carcinomatosis from CRC Historically, a devastating problem Extreme morbidity from disease
More informationAppendix adenocarcinomas are rare and heterogeneous
ORIGINAL CONTRIBUTION Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma Omer Aziz, Ph.D., F.R.C.S. 1,2 Ihab Jaradat, F.R.C.S. 1 Bipasha
More informationTreatment of peritoneal metastases from colorectal cancer
Gastroenterology Report, 3(4), 2015, 298 302 doi: 10.1093/gastro/gov044 Advance Access Publication Date: 30 September 2015 Review REVIEW Treatment of peritoneal metastases from colorectal cancer Loreen
More informationUniversity of Groningen
University of Groningen Impact of Versus Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Hentzen,
More informationRationale for the treatment. Peritoneal Surface Malignancy
Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten 05/10/12 A full circle :acknowledgements Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten
More informationU T C H. No disclosure
D U GOG T C H Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer: OVHIPEC-2 Willemien van
More informationClinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: March 2015 Page: 1 of 32 Intraperitoneal Chemotherapy for Select Intra- Description Pseudomyxoma peritonei describes extensive mucus accumulation within the peritoneum resulting
More informationSurgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
More informationThe Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors Irene Thomassen 1,2, Yvette R. van Gestel 2, Bert van Ramshorst
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: December 2016 Page: 1 of 29 Intraperitoneal Chemotherapy for Select Intra- Description Cytoreductive surgery (CRS) comprises peritonectomy (ie, peritoneal stripping) procedures
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
More informationManagement of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms
Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms Dr. Claudia LY WONG, Department of Surgery, Kwong Wah Hospital Joint Hospital Surgical Grand Round Presentation,
More informationPrimary tumor with synchronous metastases
Metastatic colorectal cancer: special clinical situations Primary tumor with synchronous metastases Stefan Heinrich & Hauke Lang Department of General, Visceral and Transplantation Surgery University Hospital
More informationNever mistake knowledge for wisdom. One helps you make a living; the other helps you make a life.
Never mistake knowledge for wisdom. One helps you make a living; the other helps you make a life. -Sandra Carey In honour of God and to my loving wife, Helena, and our children List of Papers This thesis
More informationCurative treatment of colorectal peritoneal carcinomatosis: Current status and future trends
Curative treatment of colorectal peritoneal carcinomatosis: Current status and future trends Léon Maggiori, Dominique Elias To cite this version: Léon Maggiori, Dominique Elias. Curative treatment of colorectal
More informationORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2011) 18: DOI /s
Ann Surg Oncol (2011) 18:1575 1581 DOI 10.1245/s10434-011-1631-5 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients
More informationHepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol (2011) 18:1052 1059 DOI 10.1245/s10434-010-1415-3 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationVic J. Verwaal, MD, PhD, 1 Sjoerd Bruin, MD, 1 Henk Boot, MD, PhD, 2 Gooike van Slooten, MD, 1 and Harm van Tinteren, ScM 3
Annals of Surgical Oncology 15(9):2426 2432 DOI: 10.1245/s10434-008-9966-2 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationTrattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica
Trattamento chirurgico delle lesioni epatiche secondarie difficili Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica What does it mean difficult lesions? Diagnosis Treatment Small size Unfit
More informationClinical Study Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC
Gastroenterology Research and Practice Volume 2012, Article ID 141585, 7 pages doi:10.1155/2012/141585 Clinical Study Prevention of Peritoneal Metastases from Colon Cancer in High-Risk : Preliminary Results
More informationBehandelingsmogelijkheden bij het maagcarcinoom: HIPEC. Johanna van Sandick, NKI-AvL, Amsterdam
Behandelingsmogelijkheden bij het maagcarcinoom: HIPEC Johanna van Sandick, NKI-AvL, Amsterdam Gastric cancer treatment with curative intent Macdonald et al. NEJM 2001 Cunningham et al. NEJM 2006 CRITICS
More informationDepartment of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2
Gastroenterology Research and Practice Volume 2012, Article ID 836425, 5 pages doi:10.1155/2012/836425 Clinical Study Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationLaparoscopic Resection Of Colon & Rectal Cancers. R Sim Centre for Advanced Laparoscopic Surgery, TTSH
Laparoscopic Resection Of Colon & Rectal Cancers R Sim Centre for Advanced Laparoscopic Surgery, TTSH Feasibility and safety Adequacy - same radical surgery as open op. Efficacy short term benefits and
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationMP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None
Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationONLINE CONTINUING EDUCATION ACTIVITY
ONLINE CONTINUING EDUCATION ACTIVITY Take free quizzes online at acsjournals.com/ce ARTICLE TITLE: Looking Up: Recent Advances in Understanding and Treating Peritoneal Carcinomatosis CONTINUING MEDICAL
More informationState of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options
State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options Ioannis S. Hatzaras, MD, MPH, FACS Assistant Professor of Surgery Division of Surgical Oncology
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More informationCytoreductive Strategies in the Treatment of Carcinomatosis of Colorectal Origin: Results of a Transdisciplinary National Survey
Send Orders for Reprints to reprints@benthamscience.net The Open Surgical Oncology Journal, 2013, 4, 1-6 1 Open Access Cytoreductive Strategies in the Treatment of Carcinomatosis of Colorectal Origin:
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationCRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal K. Van der Speeten, MD, PhD Pretoria 08/10/16 2016 : the Good, the Bad and the Ugly Chemosurgery The surgery in chemosurgery
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationHeated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/heated-intraperitonealchemotherapy-hipec-for-advanced-abdominal-cancers/7091/
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal
More informationMP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
More informationKathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.
Original Article Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Kathleen A. Cummins 1, Gregory
More informationTreading the beaten path with old and new obstacles: a report from the Indian HIPEC registry
International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://tandfonline.com/loi/ihyt20 Treading the beaten path with old and new obstacles: a report from
More informationAscites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer
The American Journal of Surgery (2013) 205, 668-673 Clinical Surgery Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer
More informationManchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater
More informationAbstract EDITORIAL Madrid, Spain. Telephone:
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v23.i3.377 World J Gastroenterol 2017 January 21; 23(3): 377-381 ISSN 1007-9327 (print)
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 16 AUGUST 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal
More informationPeritoneal dissemination is a common manifestation of disease
ORIGINAL ARTICLE Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Dario Baratti, MD, Shigeki Kusamura,
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationAvailable online at EJSO 37 (2011) 148e154. Accepted 26 October 2010 Available online 18 November 2010
Available online at www.sciencedirect.com EJSO 37 (2011) 148e154 www.ejso.com Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationReview Article Pulmonary Metastasis from Pseudomyxoma Peritonei
Gastroenterology Research and Practice Volume 2012, Article ID 690256, 6 pages doi:10.1155/2012/690256 Review Article Pulmonary Metastasis from Pseudomyxoma Peritonei Toshiyuki Kitai Department of Surgery,
More informationEarly colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Frédéric Bibeau, MD, PhD Pathology department Biopathology unit Institut du Cancer de Montpellier France Quality
More informationSpecialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei
Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) of Pseudomyxoma Peritonei Document Author: Assistant Medical Director Executive Lead: Medical Director Approved by: Management
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationSurgical Treatment of Gastric Cancer
SMGr up Surgical Treatment of Gastric Cancer Igor Correia de Farias 1 *, Maria Luiza Leite de Medeiros 2, Wilson Luiz da Costa Júnior 1, Heber Salvador de Castro Ribeiro 1, Alessandro Landskron Diniz 1,
More informationKaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi
Case Reports in Surgery Volume 2016, Article ID 4548798, 5 pages http://dx.doi.org/10.1155/2016/4548798 Case Report Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid
More informationCytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review past, present and future
Review Article Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review past, present and future Ahmed Dehal 1 *, J. Joshua Smith 2 *, Garrett M. Nash 2 1 Kaiser Permanente, Fontana,
More informationColorectal Liver Metastases Metachronous
Colorectal Liver Metastases Metachronous Professor Rowan Parks Professor of Surgical Sciences University of Edinburgh No disclosures Natural History of Unresected Untreated Colorectal Metastases Year N
More informationCURRICULUM VITAE 2005
CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD 69695 Pierre Bénite, France e-mail : olivier.glehen@chu-lyon.fr
More informationJoseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationBeate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR
Chairs Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Frédéric Bibeau, Caen University
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019
More informationCytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei
Int J Colorectal Dis (2005) 20:155 160 DOI 10.1007/s00384-004-0648-7 O R I G I N A L A R T I C L E Z. Güner U. Schmidt M. H. Dahlke H. J. Schlitt J. Klempnauer P. Piso Cytoreductive surgery and intraperitoneal
More informationTreatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
More informationCOLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP278 Section: Medical Benefit Policy Subject: Hyperthermia in Cancer Therapy (e.g., HIPEC) I. Policy: Hyperthermia in Cancer Therapy (e.g., HIPEC) II. Purpose/Objective:
More informationContents. Part 1. Peritoneal Carcinomatosis: Basic Concepts
Contents Part 1. Peritoneal Carcinomatosis: Basic Concepts 1. Structure and Function of Mesothelial Cells... 1 Introduction... 1 Structure of Mesothelial Cells... 1 Mesothelial Cell Functions... 3 Slippery
More informationShort and longterm outcomes after endoscopic resection of malignant polyps.
Short and longterm outcomes after endoscopic resection of malignant polyps. Short and longterm outcomes High risk features Lymph node metastasis Lymph node metastases sm1 sm2 sm3 Son 2008 3.1 % 14.9% 25.0
More information1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011
International Scholarly Research Network ISRN Oncology Volume 2011, Article ID 526384, 6 pages doi:10.5402/2011/526384 Research Article Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of complete cytoreduction Introduction (Sugarbaker technique) for pseudomyxoma peritonei
More information